NCT02184767View on ClinicalTrials.gov

Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

May 31, 2015

Conditions

BiPolar

Interventions

DRUG

ADASUVE®

ADASUVE® 2.5, 5, or 10 mg

Trial Locations (2)

Unknown

Teva Investigational Site 12468, Atlanta

Teva Investigational Site 12469, Cincinnati

All Listed Sponsors

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT02184767 - Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication | Biotech Hunter | Biotech Hunter